Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPACT-MI
NCT04509674Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of empagliflozin in myocardial infarction (MI), sponsored by Boehringer Ingelheim. Started Dec 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04509674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509674.